Observational studyCritical care science2026
Monotherapy versus combination therapy for treatment of carbapenem-resistant Acinetobacter baumannii complex infections: results from an observational study.
Observational study in Critical care science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of monotherapy versus combination therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
methodsA retrospective observational study was conducted in two tertiary hospitals in Brazil from 2018 to 2022. Patients diagnosed with bloodstream infections or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii were included. Data on demographics, clinical characteristics, antimicrobial regimens, and outcomes were collected. Statistical analyses, including multivariate logistic regression, were performed to identify predictors of mortality.
resultsAmong 123 patients (median age: 61 years), 86.2% were treated in the intensive care unit, 28-day mortality was 59,3%, and the overall mortality was 73.2%. Combination therapy was more frequently used (75.6%) and typically involved polymyxin-based regimens (71.5%). Sulbactam-containing regimens were employed in 16.3% of cases. Monotherapy was more common in ventilator-associated pneumonia (33.3%) than in bloodstream infections (14%). Mortality rates were similar between monotherapy and combination therapy (73.3% versus 73.1%; p = 0.982). In the multivariable logistic regression model, only the APACHE II score (OR = 1.12; 95%CI 1.05 - 1.21; p = 0.001) remained independently associated with mortality. Sulbactam-based therapy was not independently associated with survival (OR = 0.80; 95%CI 0.22 - 2.85; p = 0.725).
conclusionOur findings suggest that neither monotherapy nor combination therapy is associated with lower mortality in this cohort of carbapenem-resistant Acinetobacter baumannii infections, likely due to the severity of the baseline illness. Further prospective studies are needed to confirm these results and refine treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.